Severity assessment to guide empiric antibiotic therapy for cholangitis in children after Kasai portoenterostomy: a multicenter prospective randomized control trial in China

Pei Wang, Hongyi Zhang, Jixin Yang, Tianqi Zhu, Xiaojuan Wu, Bin Yi, Xiaoyi Sun, Bin Wang, Tao Wang, Weibing Tang, Hua Xie, Jinfa Tou, Yijiang Han, Xiang Liu, Jianghua Zhan, Yuanmei Liu, Yingchao Li, Zhibao Lv, Lu Li, Baohong Zhao, Tingliang Fu, Dianming Wu, Jianxi Bai, Wanfu Li, Heying Yang, Guofeng Zhang, Hongxia Ren, Jiexiong FengInternational Journal of Surgery 2023 · DOI

TL;DR

This study introduces a novel severity grading system for post-Kasai portoenterostomy (KPE) cholangitis in children, demonstrating its effectiveness in guiding empiric antibiotic therapy. The findings suggest that cefoperazone is sufficient for mild cases, meropenem is optimal for moderate cases, and a combination of meropenem with intravenous immunoglobulin (IVIG) offers improved short-term outcomes for severe cases.

What Problem Does This Paper Address?

Biliary atresia (BA) is a serious condition in infants characterized by the progressive blockage of bile ducts, often leading to cholestatic jaundice. Kasai portoenterostomy (KPE) is the primary surgical intervention to restore bile flow. However, cholangitis, an inflammation of the bile ducts, is a frequent and serious complication following KPE, occurring in a significant percentage of patients. Prompt and appropriate antibiotic treatment is crucial for managing cholangitis, especially since identifying the specific causative microorganisms can be challenging, with positive blood culture rates often being low. Current treatment strategies for cholangitis after KPE often rely on broad-spectrum antibiotics, but there's a need for a more refined approach that considers disease severity to optimize treatment, reduce antibiotic resistance, and improve patient outcomes. This paper addresses the need for a validated severity assessment tool to guide the selection of empiric antibiotic therapy for post-KPE cholangitis.

Methods

The study employed a multicenter, prospective, randomized, open-label trial design involving 14 hospitals in China. Patients diagnosed with post-KPE cholangitis were categorized into three severity grades: mild, moderate, and severe, based on a newly proposed grading system that considers temperature, white blood cell (WBC) count, and C-reactive protein (CRP) levels.

  • Mild Cholangitis: Patients were randomized to receive either cefoperazone sodium tazobactam sodium (CSTS) or meropenem (MEPM).
  • Moderate Cholangitis: Patients received MEPM.
  • Severe Cholangitis: Patients were randomized to receive either MEPM or MEPM combined with intravenous immunoglobulin (MEPM + IVIG).

The primary endpoint was the duration of fever (DOF). Secondary outcomes included blood culture results, length of hospital stay (LOS), incidence of recurrent cholangitis, jaundice clearance rate, and native liver survival (NLS) at 1, 3, and 6 months post-discharge. Statistical analyses included intention-to-treat principles, with continuous variables analyzed using t-tests or Wilcoxon rank-sum tests, and categorical variables using chi-squared or Fisher's exact tests.

Datasets

Not discussed in the paper. The study involved patient data collected during the clinical trial.

Key Insights and Ideas

  • Severity-Guided Therapy is Feasible and Effective: The developed severity grading system proved to be a practical tool for tailoring antibiotic choices, leading to potentially better outcomes.
  • Cefoperazone Remains a Viable Option for Mild Cases: For mild cholangitis, CSTS demonstrated comparable efficacy to MEPM in terms of fever duration and other clinical outcomes, suggesting it can be a cost-effective first-line treatment.
  • Meropenem is the Standard for Moderate Cholangitis: The study reinforces the use of MEPM as the optimal empiric antibiotic for moderate cholangitis.
  • IVIG as a Promising Adjunct for Severe Cholangitis: The addition of IVIG to MEPM in severe cases showed significant improvements in short-term clinical outcomes, including reduced fever duration and improved liver function markers, highlighting its potential role in managing more critical infections.
  • Enterococcus faecalis Dominates in Severe Cases: The study identified Enterococcus faecalis as the most common pathogen in moderate and severe cholangitis, a finding that could inform future empirical treatment strategies.

Key Results

  • Mild Cholangitis: No significant difference in DOF or LOS was observed between CSTS and MEPM.
  • Moderate Cholangitis: The DOF was 36.00 (IQR: 24.00–48.00) hours.
  • Severe Cholangitis: MEPM + IVIG significantly decreased DOF compared to MEPM alone (52.00 vs. 68.00 hours, P=0.001) and improved liver function markers at 1-month follow-up. However, long-term outcomes like NLS and recurrence rates did not differ significantly between the MEPM and MEPM + IVIG groups.
  • Blood Culture Positivity: Overall, 15.17% of patients had positive blood cultures. The rate was highest in severe cholangitis (25.93%).
  • Recurrent Cholangitis: While no recurrent cholangitis was observed at 7 days, the incidence was significantly higher in the severe cholangitis group compared to the mild group at 1, 3, and 6 months.

Limitations and Future Work

  • Open-Label Design: The study was open-label, meaning participants and researchers were aware of the treatment allocation, which could introduce bias.
  • Relatively Small Sample Size: The study involved a moderate number of participants, particularly in the severe cholangitis groups.
  • Short-Term Follow-up: The analysis focused on outcomes up to 6 months. Long-term follow-up is needed to fully assess the impact of different treatments on native liver survival and other long-term sequelae.
  • Future Work: The authors suggest that future clinical trials should further investigate the efficacy and feasibility of IVIG in the early stages of post-KPE cholangitis. Additionally, long-term follow-up studies are recommended to evaluate the sustained benefits of the proposed severity-guided treatment approach.

Summary updated

Abstract

In patients with post-KPE cholangitis, MEPM is not superior to CSTS for the treatment of mild cholangitis. However, MEPM+IVIG treatment was associated with better short-term clinical outcomes in patients with severe cholangitis.
BibTeX
@article{wang2023severity,
  author = {Pei Wang and Hongyi Zhang and Jixin Yang and Tianqi Zhu and Xiaojuan Wu and Bin Yi and Xiaoyi Sun and Bin Wang and Tao Wang and Weibing Tang and Hua Xie and Jinfa Tou and Yijiang Han and Xiang Liu and Jianghua Zhan and Yuanmei Liu and Yingchao Li and Zhibao Lv and Lu Li and Baohong Zhao and Tingliang Fu and Dianming Wu and Jianxi Bai and Wanfu Li and Heying Yang and Guofeng Zhang and Hongxia Ren and Jiexiong Feng},
  title = {{Severity assessment to guide empiric antibiotic therapy for cholangitis in children after Kasai portoenterostomy: a multicenter prospective randomized control trial in China}},
  journal = {International Journal of Surgery},
  year = {2023},
  doi = {10.1097/js9.0000000000000682},
}
Figure